About SphynKx Therapeutics
SphynKx Therapeutics is a company based in Charlottesville (United States) founded in 2011 by Andrew Bolt. It operates as a B2B. SphynKx Therapeutics has raised $50 thousand across 5 funding rounds from investors including NIH, HHS and Center for Innovative Technology. SphynKx Therapeutics operates in a competitive market with competitors including Reneo Pharmaceuticals, Alentis Therapeutics, Sionna, Blade Therapeutics and Promedior, among others.
- Headquarter Charlottesville, United States
- Founders Andrew Bolt
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$50 K (USD)
in 5 rounds
-
Latest Funding Round
-
Investors
NIH
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of SphynKx Therapeutics
SphynKx Therapeutics has successfully raised a total of $50K across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Last Round
-
First Round
First Round
(18 Jan 2012)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2013 | Amount | Grant - SphynKx Therapeutics | Valuation |
investors |
|
| Sep, 2013 | Amount | Grant - SphynKx Therapeutics | Valuation |
investors |
|
| Jul, 2012 | Amount | Grant - SphynKx Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SphynKx Therapeutics
SphynKx Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Center for Innovative Technology. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage VC firm funding companies in the US
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SphynKx Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SphynKx Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sphynkx Therapeutics Comparisons
Competitors of SphynKx Therapeutics
SphynKx Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reneo Pharmaceuticals, Alentis Therapeutics, Sionna, Blade Therapeutics and Promedior, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Small molecule therapies for orphan diseases are being developed.
|
|
| domain | founded_year | HQ Location |
Therapies for fibrosis, cirrhosis, and liver cancer are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cystic fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
Antifibrotic strategies are developed for congenital and acquired fibrotic diseases.
|
|
| domain | founded_year | HQ Location |
Targeted protein-based therapeutics to treat fibrotic diseases such as Idiopathic Pulmonary Fibrosis, Age-Related Macular Degeneration.
|
|
| domain | founded_year | HQ Location |
Therapies for treating Idiopathic Pulmonary Fibrosis are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about SphynKx Therapeutics
When was SphynKx Therapeutics founded?
SphynKx Therapeutics was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Where is SphynKx Therapeutics located?
SphynKx Therapeutics is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Is SphynKx Therapeutics a funded company?
SphynKx Therapeutics is a funded company, having raised a total of $50K across 5 funding rounds to date. The company's 1st funding round was a Grant of $152.79K, raised on Jan 18, 2012.
What does SphynKx Therapeutics do?
SphynKx Therapeutics, based in Charlottesville, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and fibrosis treatment. Develops therapies targeted at treating fibrosis. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
Who are the top competitors of SphynKx Therapeutics?
SphynKx Therapeutics's top competitors include Arcturus Therapeutics, Reneo Pharmaceuticals and Sionna.
Who are SphynKx Therapeutics's investors?
SphynKx Therapeutics has 3 investors. Key investors include NIH, HHS, and Center for Innovative Technology.